Everand Logo

Welcome to Everand!

  • STAT

    Opinion: San Francisco’s Mission Bay life science sector: pivoting with the times

    While #MissionBay hasn't quite captured the magnitude of biotech and pharma players as has #KendallSquare in Cambridge, the growth of its life sciences industry will continue in a very Left…
    by Chris Haskell Oct 24, 2019 2 minutes
    An aerial shot of San Francisco

    Twenty years ago, San Francisco’s Mission Bay was an industrial zone filled with shipyards and railroad tracks. It was sluggish by day and deserted by night. Today, it is a vibrant health and biotech hub that continues to evolve. A note to the media: Don’t box us in.

    When my company, Bayer, relocated its California research and innovation teams to Mission Bay in 2010, the decision was

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks